AxoGen (NASDAQ:AXGN) Stock Rating Reaffirmed by JMP Securities

AxoGen (NASDAQ:AXGN – Get Rating)‘s stock had its “market outperform” rating reissued by analysts at JMP Securities in a research note issued on Wednesday, Benzinga reports. They presently have a $20.00 target price on the medical equipment provider’s stock. JMP Securities’ price target indicates a potential upside of 141.84% from the stock’s current price.

Separately, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Thursday, November 17th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $17.00.

AxoGen Stock Down 1.5 %

Shares of AXGN opened at $8.27 on Wednesday. AxoGen has a one year low of $6.87 and a one year high of $13.66. The company has a market cap of $349.74 million, a P/E ratio of -12.16 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.35 and a quick ratio of 3.54. The firm has a 50 day simple moving average of $9.21 and a two-hundred day simple moving average of $10.33.

Insider Transactions at AxoGen

In other news, CFO Peter J. Mariani sold 20,939 shares of the company’s stock in a transaction on Thursday, January 26th. The shares were sold at an average price of $9.90, for a total transaction of $207,296.10. Following the completion of the transaction, the chief financial officer now directly owns 42,108 shares in the company, valued at $416,869.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Peter J. Mariani sold 14,320 shares of the business’s stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $9.55, for a total value of $136,756.00. Following the sale, the chief financial officer now owns 55,555 shares of the company’s stock, valued at $530,550.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Peter J. Mariani sold 20,939 shares of the business’s stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $9.90, for a total transaction of $207,296.10. Following the completion of the sale, the chief financial officer now directly owns 42,108 shares in the company, valued at approximately $416,869.20. The disclosure for this sale can be found here. Company insiders own 7.51% of the company’s stock.

Institutional Trading of AxoGen

Several institutional investors have recently modified their holdings of AXGN. HighMark Wealth Management LLC grew its stake in shares of AxoGen by 851.1% in the third quarter. HighMark Wealth Management LLC now owns 2,235 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,000 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in shares of AxoGen in the third quarter worth $27,000. Lazard Asset Management LLC grew its stake in shares of AxoGen by 1,282.6% in the first quarter. Lazard Asset Management LLC now owns 5,088 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 4,720 shares during the last quarter. Royal Bank of Canada grew its stake in shares of AxoGen by 610.2% in the third quarter. Royal Bank of Canada now owns 6,129 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 5,266 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of AxoGen by 139.2% in the third quarter. Tower Research Capital LLC TRC now owns 8,909 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 5,184 shares during the last quarter. Institutional investors own 76.22% of the company’s stock.

AxoGen Company Profile

(Get Rating)

Axogen, Inc engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator.